Skip to main content

Peer Review reports

From: Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis

Original Submission
1 Nov 2023 Submitted Original manuscript
27 Nov 2023 Reviewed Reviewer Report
3 Dec 2023 Reviewed Reviewer Report
11 Dec 2023 Author responded Author comments - Wenxi Tang
12 Dec 2023 Author responded Author comments - Wenxi Tang
Resubmission - Version 2
11 Dec 2023 Submitted Manuscript version 2
12 Dec 2023 Author responded Author comments - Wenxi Tang
Resubmission - Version 3
12 Dec 2023 Submitted Manuscript version 3
2 Jan 2024 Reviewed Reviewer Report
23 Jan 2024 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
23 Jan 2024 Editorially accepted
8 Feb 2024 Article published 10.1186/s12885-024-11916-4

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us